Filter posts

Peter Pitts Examines the Role of PBMs and their Deceptive Tactics

A piece by Peter J. Pitts, a former FDA Associate Commissioner and President of the …

Vaccines Work: the Proof Is in the Data.

At the latest meeting of the Advisory Committee on Immunization Practices (ACIP), more than 80 …

Kentucky Officials Expose PBMs for Gaming the System

While many were watching the drug pricing debate unfold on Capitol Hill, the Kentucky Cabinet …

The Empty Promise of “Safe” Drug Importation

For years, BIO has been urging both state and federal policymakers to adopt responsible solutions …

Two New Infographics Illustrate the Success of the Orphan Drug Act

In recognition of Rare Disease Day, BIO’s Jim Greenwood shared commentary on LinkedIn celebrating the …

With an Air of Optimism, #BIOCEO19 Concludes

Despite considerable pressure directed squarely at biotech innovators from politicians of every stripe, biotech executives …

Venture Creation is in Vogue

In the biotech industry, it’s common for a company to raise billions of dollars and …

Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical ...

In his State of the Union address, President Trump called on Congress to “do more” …

#BIOCEO19: Navigating Payers’ Expectations for Value-Based Agreements

Value-based agreements are becoming increasingly important in the biopharmaceutical reimbursement space, particularly as new advanced …

New BIO Report on Impact of Sarbanes-Oxley 404(b) on Emerging Biotech Innovators

BIO is out with a new report illustrating the negative impact of Sarbanes-Oxley 404(b) on …